AngioDynamics (NASDAQ:ANGO) Releases Earnings Results, Beats Estimates By $0.02 EPS

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02, Zacks reports. The firm had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company’s quarterly revenue was up 12.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) earnings per share. AngioDynamics updated its FY 2026 guidance to -0.330–0.230 EPS.

AngioDynamics Stock Down 0.9%

Shares of ANGO opened at $11.64 on Friday. AngioDynamics has a 52 week low of $5.83 and a 52 week high of $13.50. The company has a market capitalization of $478.17 million, a price-to-earnings ratio of -14.92 and a beta of 0.78. The stock’s 50-day moving average price is $9.94 and its 200-day moving average price is $9.76.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Saturday, September 27th. Canaccord Genuity Group raised their price objective on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of AngioDynamics in a research note on Wednesday, July 16th. Finally, Lake Street Capital started coverage on AngioDynamics in a research report on Wednesday, July 16th. They set a “buy” rating and a $24.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, AngioDynamics presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership lifted its position in shares of AngioDynamics by 8.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 583,675 shares of the medical instruments supplier’s stock valued at $5,790,000 after acquiring an additional 43,573 shares in the last quarter. Manatuck Hill Partners LLC grew its stake in shares of AngioDynamics by 7.7% in the second quarter. Manatuck Hill Partners LLC now owns 350,000 shares of the medical instruments supplier’s stock valued at $3,472,000 after buying an additional 25,000 shares in the last quarter. Bank of America Corp DE grew its stake in shares of AngioDynamics by 729.4% in the second quarter. Bank of America Corp DE now owns 286,208 shares of the medical instruments supplier’s stock valued at $2,839,000 after buying an additional 251,702 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of AngioDynamics by 9.6% in the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after buying an additional 22,658 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of AngioDynamics by 2.2% in the second quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier’s stock valued at $1,216,000 after buying an additional 2,667 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.